Progenics Pharmaceuticals, Inc. (PGNX) Shares Bought by Schwab Charles Investment Management Inc.

Schwab Charles Investment Management Inc. increased its position in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) by 8.2% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 391,345 shares of the biotechnology company’s stock after buying an additional 29,724 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.52% of Progenics Pharmaceuticals worth $3,147,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also recently added to or reduced their stakes in the stock. Rice Hall James & Associates LLC lifted its position in Progenics Pharmaceuticals by 1.1% in the 2nd quarter. Rice Hall James & Associates LLC now owns 1,389,840 shares of the biotechnology company’s stock worth $11,174,000 after buying an additional 15,378 shares during the last quarter. Bank of New York Mellon Corp lifted its position in Progenics Pharmaceuticals by 2.3% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,062,981 shares of the biotechnology company’s stock worth $8,546,000 after buying an additional 24,073 shares during the last quarter. Summit Trail Advisors LLC lifted its position in Progenics Pharmaceuticals by 529.5% in the 1st quarter. Summit Trail Advisors LLC now owns 408,376 shares of the biotechnology company’s stock worth $408,000 after buying an additional 343,505 shares during the last quarter. JPMorgan Chase & Co. lifted its position in Progenics Pharmaceuticals by 268.7% in the 1st quarter. JPMorgan Chase & Co. now owns 326,562 shares of the biotechnology company’s stock worth $2,436,000 after buying an additional 237,992 shares during the last quarter. Finally, Allianz Asset Management GmbH lifted its position in Progenics Pharmaceuticals by 17.8% in the first quarter. Allianz Asset Management GmbH now owns 234,314 shares of the biotechnology company’s stock valued at $1,748,000 after purchasing an additional 35,462 shares during the last quarter. Institutional investors own 88.74% of the company’s stock.

Shares of PGNX stock opened at $5.92 on Tuesday. The company has a quick ratio of 6.34, a current ratio of 6.34 and a debt-to-equity ratio of 0.68. Progenics Pharmaceuticals, Inc. has a fifty-two week low of $5.01 and a fifty-two week high of $9.42. The company has a market capitalization of $472.50 million, a price-to-earnings ratio of -6.58 and a beta of 2.50.

Progenics Pharmaceuticals (NASDAQ:PGNX) last announced its quarterly earnings data on Tuesday, July 31st. The biotechnology company reported ($0.20) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by ($0.02). Progenics Pharmaceuticals had a negative net margin of 341.41% and a negative return on equity of 94.45%. The company had revenue of $3.88 million during the quarter, compared to the consensus estimate of $3.30 million. On average, equities analysts predict that Progenics Pharmaceuticals, Inc. will post -0.67 EPS for the current year.

PGNX has been the subject of several recent research reports. ValuEngine downgraded Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, August 29th. Needham & Company LLC downgraded Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating and lowered their price objective for the company from $16.00 to $12.00 in a research report on Thursday, September 13th. Jefferies Financial Group reiterated a “buy” rating and issued a $13.00 price objective on shares of Progenics Pharmaceuticals in a research report on Wednesday, August 1st. BidaskClub downgraded Progenics Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 19th. Finally, Zacks Investment Research upgraded Progenics Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, September 11th. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. Progenics Pharmaceuticals presently has an average rating of “Buy” and a consensus target price of $11.69.

Progenics Pharmaceuticals Profile

Progenics Pharmaceuticals, Inc develops medicines and other technologies to target and treat cancer in the United States and internationally. The company's primary clinical-stage product candidates include Azedra, a radiotherapeutic product candidate, which is in Phase IIb clinical trial under special protocol assessment for the treatment of malignant, recurrent, and/or unresectable pheochromocytoma and paraganglioma; 1404, a technetium-99m labeled small molecule, which is in Phase III clinical trial that acts as an imaging agent to diagnose and detect prostate cancer, as well as soft tissue and bone metastases; and PyL, a fluorinated prostate specific membrane antigen (PSMA)-targeted positron emission topography (PET) imaging agent for prostate cancer.

Recommended Story: How Investors Use a Balance Sheet

Institutional Ownership by Quarter for Progenics Pharmaceuticals (NASDAQ:PGNX)

Receive News & Ratings for Progenics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Progenics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply